These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

175 related articles for article (PubMed ID: 15755124)

  • 1. Synthesis of the potent immunostimulatory adjuvant QS-21A.
    Wang P; Kim YJ; Navarro-Villalobos M; Rohde BD; Gin DY
    J Am Chem Soc; 2005 Mar; 127(10):3256-7. PubMed ID: 15755124
    [TBL] [Abstract][Full Text] [Related]  

  • 2. Synthetic studies of complex immunostimulants from Quillaja saponaria: synthesis of the potent clinical immunoadjuvant QS-21Aapi.
    Kim YJ; Wang P; Navarro-Villalobos M; Rohde BD; Derryberry J; Gin DY
    J Am Chem Soc; 2006 Sep; 128(36):11906-15. PubMed ID: 16953631
    [TBL] [Abstract][Full Text] [Related]  

  • 3. Synthesis and structure verification of the vaccine adjuvant QS-7-Api. Synthetic access to homogeneous Quillaja saponaria immunostimulants.
    Deng K; Adams MM; Gin DY
    J Am Chem Soc; 2008 May; 130(18):5860-1. PubMed ID: 18410100
    [TBL] [Abstract][Full Text] [Related]  

  • 4. Semisynthesis of Analogues of the Saponin Immunoadjuvant QS-21.
    Fernández-Tejada A; Walkowicz WE; Tan DS; Gin DY
    Methods Mol Biol; 2017; 1494():45-71. PubMed ID: 27718185
    [TBL] [Abstract][Full Text] [Related]  

  • 5. Development of Improved Vaccine Adjuvants Based on the Saponin Natural Product QS-21 through Chemical Synthesis.
    Fernández-Tejada A; Tan DS; Gin DY
    Acc Chem Res; 2016 Sep; 49(9):1741-56. PubMed ID: 27568877
    [TBL] [Abstract][Full Text] [Related]  

  • 6. Design and synthesis of potent Quillaja saponin vaccine adjuvants.
    Adams MM; Damani P; Perl NR; Won A; Hong F; Livingston PO; Ragupathi G; Gin DY
    J Am Chem Soc; 2010 Feb; 132(6):1939-45. PubMed ID: 20088518
    [TBL] [Abstract][Full Text] [Related]  

  • 7. Synthesis of the trisaccharide portion of the immunologic adjuvant QS-21A via sulfonium-mediated oxidative and dehydrative glycosylation.
    Kim YJ; Gin DY
    Org Lett; 2001 Jun; 3(12):1801-4. PubMed ID: 11405715
    [TBL] [Abstract][Full Text] [Related]  

  • 8. Advances in saponin-based adjuvants.
    Sun HX; Xie Y; Ye YP
    Vaccine; 2009 Mar; 27(12):1787-96. PubMed ID: 19208455
    [TBL] [Abstract][Full Text] [Related]  

  • 9. Separation and characterization of saponins with adjuvant activity from Quillaja saponaria Molina cortex.
    Kensil CR; Patel U; Lennick M; Marciani D
    J Immunol; 1991 Jan; 146(2):431-7. PubMed ID: 1987271
    [TBL] [Abstract][Full Text] [Related]  

  • 10. QS-21 and QS-7: purified saponin adjuvants.
    Kensil CR; Wu JY; Anderson CA; Wheeler DA; Amsden J
    Dev Biol Stand; 1998; 92():41-7. PubMed ID: 9554258
    [TBL] [Abstract][Full Text] [Related]  

  • 11. Natural and synthetic saponin adjuvant QS-21 for vaccines against cancer.
    Ragupathi G; Gardner JR; Livingston PO; Gin DY
    Expert Rev Vaccines; 2011 Apr; 10(4):463-70. PubMed ID: 21506644
    [TBL] [Abstract][Full Text] [Related]  

  • 12. Synthesis and Evaluation of QS-7-Based Vaccine Adjuvants.
    Wang P; Škalamera Đ; Sui X; Zhang P; Michalek SM
    ACS Infect Dis; 2019 Jun; 5(6):974-981. PubMed ID: 30920199
    [TBL] [Abstract][Full Text] [Related]  

  • 13. QS-21 Adjuvant: Laboratory-Scale Purification Method and Formulation Into Liposomes.
    Brunner L; Barnier-Quer C; Collin N
    Methods Mol Biol; 2017; 1494():73-86. PubMed ID: 27718186
    [TBL] [Abstract][Full Text] [Related]  

  • 14. Synthesis and Evaluation of a QS-17/18-Based Vaccine Adjuvant.
    Wang P; Škalamera Đ; Sui X; Zhang P; Michalek SM
    J Med Chem; 2019 Feb; 62(3):1669-1676. PubMed ID: 30656932
    [TBL] [Abstract][Full Text] [Related]  

  • 15. Structure of the saponin adjuvant QS-21 and its base-catalyzed isomerization product by 1H and natural abundance 13C NMR spectroscopy.
    Jacobsen NE; Fairbrother WJ; Kensil CR; Lim A; Wheeler DA; Powell MF
    Carbohydr Res; 1996 Jan; 280(1):1-14. PubMed ID: 8581890
    [TBL] [Abstract][Full Text] [Related]  

  • 16. Design, synthesis, and immunologic evaluation of vaccine adjuvant conjugates based on QS-21 and tucaresol.
    Fernández-Tejada A; Chea EK; George C; Gardner JR; Livingston PO; Ragupathi G; Tan DS; Gin DY
    Bioorg Med Chem; 2014 Nov; 22(21):5917-23. PubMed ID: 25284254
    [TBL] [Abstract][Full Text] [Related]  

  • 17. Isomerization and formulation stability of the vaccine adjuvant QS-21.
    Cleland JL; Kensil CR; Lim A; Jacobsen NE; Basa L; Spellman M; Wheeler DA; Wu JY; Powell MF
    J Pharm Sci; 1996 Jan; 85(1):22-8. PubMed ID: 8926578
    [TBL] [Abstract][Full Text] [Related]  

  • 18. Synthesis of QS-21-xylose: establishment of the immunopotentiating activity of synthetic QS-21 adjuvant with a melanoma vaccine.
    Deng K; Adams MM; Damani P; Livingston PO; Ragupathi G; Gin DY
    Angew Chem Int Ed Engl; 2008; 47(34):6395-8. PubMed ID: 18624313
    [No Abstract]   [Full Text] [Related]  

  • 19. Vaccine adjuvant systems containing monophosphoryl lipid A and QS21 induce strong and persistent humoral and T cell responses against hepatitis B surface antigen in healthy adult volunteers.
    Vandepapelière P; Horsmans Y; Moris P; Van Mechelen M; Janssens M; Koutsoukos M; Van Belle P; Clement F; Hanon E; Wettendorff M; Garçon N; Leroux-Roels G
    Vaccine; 2008 Mar; 26(10):1375-86. PubMed ID: 18272264
    [TBL] [Abstract][Full Text] [Related]  

  • 20. Adjuvant activity of Quillaja brasiliensis saponins on the immune responses to bovine herpesvirus type 1 in mice.
    Fleck JD; Kauffmann C; Spilki F; Lencina CL; Roehe PM; Gosmann G
    Vaccine; 2006 Nov; 24(49-50):7129-34. PubMed ID: 16887242
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 9.